Investors & Media

We are developing and applying powerful screening pipelines that identify new, efficacious drug targets in cancers to help patients live longer, better lives. Our approach combines expertise in genomic gene essentiality screens with powerful drug-identification bioinformatics programs, optimized by proprietary prediction programs and drug sensitivity validation assays.